Trials / Terminated
TerminatedNCT05048134
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
A Multi-center, Open-Label，Dose Escalation and Dose Expansion Phase I Study of HRS2300 Monotherapy or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety and tolerability of HRS2300 and combined with SHR-1316 or SHR-1701 or trametinib or Almonertinib.To Determine the maximum tolerated dose (MTD) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS2300 | HRS2300 monotherapy |
| DRUG | HRS2300、 SHR-1316 | HRS2300 combined with SHR-1316 |
| DRUG | HRS2300、SHR-1701 | HRS2300 combined with SHR-1701 |
| DRUG | HRS2300、trametinib | HRS2300 combined with trametinib |
| DRUG | HRS2300、Almonertinib | HRS2300 combined with Almonertinib |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2023-02-24
- Completion
- 2023-05-23
- First posted
- 2021-09-17
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05048134. Inclusion in this directory is not an endorsement.